Moderna, Inc. (MRNA) income statement
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 23.4%
- Operating margin
- -149.0%
- Net margin
- -141.4%
- Return on equity, FY2025
- -28.9%
Financial strength
- Current ratio
- 2.29
- Debt to equity
- 0.09
- Debt to assets
- 5.4%
- Cash to current liabilities
- 68.0%
Valuation
- P/E ratio
- –
- Price to sales
- 35.26
- Price to book
- 11.62
- Dividend yield
- –
See a number that looks wrong?